Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic

Abstract Immune-checkpoint inhibitors (ICIs) can cause inflammation and immune-related adverse events (irAEs). Although irAEs may be caused by dysregulation of cytokines, the impact of various COVID- 19-related factors on expression of ICI-related AEs remains unclear. Assessment of AEs following ICI...

Full description

Bibliographic Details

Published in:	BMC Immunology
Main Authors:	Sakiko Kimura, Hiroo Katsuya, Chiho Nakashima, Naoko Sueoka-Aragane, Koji Hayashida, Kazumi Sasaki, Rintaro Sogawa, Tatsuya Furuno, Moriyasu Yamauchi, Yoichiro Sugiyama, Hirokazu Noshiro, Motohiro Esaki, Mitsuru Noguchi, Hirokazu Takahashi, Keizo Anzai, Masatoshi Yokoyama, Kazunari Sugita, Yoshio Yamashita, Atsushi Kawaguchi, Shinya Kimura, Chisato Shimanoe
Format:	Article
Language:	English
Published:	BMC 2025-04-01
Subjects:	Immune-checkpoint inhibitor Adverse events COVID- 19 pandemic
Online Access:	https://doi.org/10.1186/s12865-025-00711-w